GT 307 / Grit Biotechnology - LARVOL DELTA

Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients with Advanced Colorectal Cancer (clinicaltrials.gov) - P=N/A | N=18 | Recruiting | Sponsor: Grit Biotechnology

New trial • Colorectal Cancer • Oncology • Solid Tumor

Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours (clinicaltrials.gov) - P=N/A | N=18 | Recruiting | Sponsor: Grit Biotechnology

New trial • Oncology • Solid Tumor

Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours (clinicaltrials.gov) - P=N/A | N=18 | Recruiting | Sponsor: Grit Biotechnology

New trial • Oncology • Solid Tumor

A CRISPR/Cas9 screening platform ImmuT Finder® enables in vivo T cell functional screening and identification of potent immunoregulatory targets for next-generation T cell therapy (AACR 2024) - "Furthermore, GT307 KO TCR-T and TIL demonstrated significantly improved tumor control in mouse models than their unedited counterparts and promoted long-term persistence with low support of IL-2. In summary, these data demonstrated that our ImmuT Finder® platform enables discovery of potent and/or novel targets for the development of T cell product and supports the clinical assessment of GT307 as a next-generation T cell therapy."

Preclinical • Oncology • Solid Tumor • IL2